mgd024
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2022 (NCT05362773)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E
- Interleukin-3 receptor subunit alphaBINDING AGENT
IL3RA binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05362773 | Phase 1 | Jul 13, 2022 | MacroGenics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MacroGenics | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1